Last updated on November 2017

A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD


Brief description of study

A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD

Detailed Study Description

This study is being done to learn more about the study drug, Nintedanib, and to learn if there are blood tests that can help see how the study drug affects IPF.

Clinical Study Identifier: TX11565

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Kathleen McNulty, MHS, CCRC

The Lung Research Center
Chesterfield, MO USA
  Connect »